J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
The Journal of Clinical Pharmacology and New Drugs, 1972; 12:40-45
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brown, G. L.
Right arrow Articles by Martin, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brown, G. L.
Right arrow Articles by Martin, R. M., JR.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Double-Blind, Noncrossover Study of Imipramine and A-10749

G. LaVonne Brown M.D.1, Robert L. Green JR. M.D.2, and Robert M. Martin JR. M.D.3

1 Duke University Medical Center and Veterans Administration Hospital, Durham, North Carolina.
2 Duke University Medical Center; Psychiatry Service, Veterans Administration Hospital, Durham, North Carolina.
3 Duke University Medical Center; Veterans Administration Hospital, Durham, North Carolina.

Because of its antidepressant activity, somewhat less than that of imipramine in the patient group studied, and its low order of side effects, A-10749 deserves further investigation as a clinically useful drug. As an antidepressant similar in its effects to imipramine (using the modified DOPA test), but with other significantly different properties chemically and pharmacologically, A-10749 also deserves further study, particularly in terms of its effect on tryptophan metabolism.

Note:

The authors wish to express their appreciation to E. Dixon Holland, M.D., Associate Director, Abbott Laboratories Scientific Division, North Chicago, Illinois.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1972 by the American College of Clinical Pharmacology